Famotidine* (Famotidine) — Medicare Part D spending
Multiple manufacturers (31) · Rank #215 by total Part D spend · CMS data year 2023
Medicare Part D spent $202,810,000 on Famotidine* (Famotidine) in 2023, the #215 drug by total Part D spending out of 3,598 drugs. That worked out to about $0.20 per dosage unit, $16 per claim and $56 per beneficiary, across 12,748,534 claims for 3,593,191 beneficiaries. Average spending per dosage unit rose +4.2% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Famotidine* (Famotidine) spending at a glance (2023)
| Metric | Famotidine* (Famotidine) |
|---|---|
| Total Part D spending (2023) | $202,810,000 |
| Total spending (2022) | $181,467,010 |
| Year-over-year change in total spending | +11.8% |
| Average spending per dosage unit (2023) | $0.20 |
| Change in spend per dosage unit (YoY) | +4.2% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +3.1% |
| Average spending per claim (2023) | $16 |
| Average spending per beneficiary (2023) | $56 |
| Total claims (2023) | 12,748,534 |
| Beneficiaries (2023) | 3,593,191 |
| Total dosage units (2023) | 996,904,057 |
| Manufacturer(s) | Multiple manufacturers (31) |
| National rank by total spend (of 3,598 drugs) | #215 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $181,467,010 | $202,810,000 | +11.8% |
| Avg spend per dosage unit | $0.19 | $0.20 | +4.2% |
| Avg spend per claim | $16 | $16 | — |
| Avg spend per beneficiary | $55 | $56 | — |
| Total claims | 11,671,755 | 12,748,534 | — |
| Beneficiaries | 3,301,424 | 3,593,191 | — |
How Famotidine* compares with nearby drugs
Drugs with total Part D spending closest to Famotidine* (Famotidine):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Famotidine* (Famotidine) (this drug, #215) | $202,810,000 | $0.20 | +4.2% |
| Cosentyx Sensoready Pen (Secukinumab) (#213) | $205,397,019 | $7,222.37 | +9.0% |
| Lokelma (Sodium Zirconium Cyclosilicate) (#214) | $205,055,771 | $27.18 | +6.6% |
| Clopidogrel (Clopidogrel Bisulfate) (#216) | $201,696,339 | $0.24 | -1.0% |
| Fluticasone Propionate* (Fluticasone Propionate) (#217) | $201,536,224 | $0.69 | -2.4% |
| Quetiapine Fumarate (#218) | $201,087,913 | $0.42 | -27.7% |
Frequently asked questions
How much does Medicare Part D spend on Famotidine*?
Medicare Part D spent $202,810,000 on Famotidine* (Famotidine) in 2023 (the latest CMS data year), across 12,748,534 claims for 3,593,191 beneficiaries. That ranks #215 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Famotidine*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Famotidine* (Famotidine) was $0.20. Compared with 2022 it rose +4.2%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Famotidine*?
CMS attributes Famotidine* (Famotidine) to Multiple manufacturers (31) in the 2023 Part D spending file. Average spending per claim was $16 and per beneficiary $56.
Is the Famotidine* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20